Yanchen Zhou

1.8k total citations · 1 hit paper
29 papers, 1.3k citations indexed

About

Yanchen Zhou is a scholar working on Immunology, Infectious Diseases and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Yanchen Zhou has authored 29 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 5 papers in Infectious Diseases and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Yanchen Zhou's work include SARS-CoV-2 and COVID-19 Research (4 papers), Viral Infections and Outbreaks Research (4 papers) and Migraine and Headache Studies (3 papers). Yanchen Zhou is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (4 papers), Viral Infections and Outbreaks Research (4 papers) and Migraine and Headache Studies (3 papers). Yanchen Zhou collaborates with scholars based in United States, China and Germany. Yanchen Zhou's co-authors include Graham Simmons, Kai Lü, Stefan Pöhlmann, Dale L. Barnard, James H. McKerrow, Juliet Agudelo, P. Vedantham, Jerritt Nunneley, Ricardo Carrion and Adam R. Renslo and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Yanchen Zhou

28 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protease inhibitors targeting coronavirus and filovirus entry

2015 437 citations Yanchen Zhou, P. Vedantham et al. Antiviral Research profile →

Peers

Countries citing papers authored by Yanchen Zhou

Since Specialization

Citations

This map shows the geographic impact of Yanchen Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanchen Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanchen Zhou more than expected).

Fields of papers citing papers by Yanchen Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanchen Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanchen Zhou. The network helps show where Yanchen Zhou may publish in the future.

Co-authorship network of co-authors of Yanchen Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Yanchen Zhou. A scholar is included among the top collaborators of Yanchen Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanchen Zhou. Yanchen Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Photonic axion insulator with non-coplanar chiral hinge transport 2025 ·Nature Communications ·(unknown), Yanchen Zhou, (unknown), Cheng He, Yan‐Feng Chen	0
2	Observation of Photonic Chern Metal With Bi‐Chiral Edge Propagation 2024 ·Laser & Photonics Review ·Yanchen Zhou, (unknown), (unknown), Xiaochen Sun, Cheng He, Yan‐Feng Chen	3
3	Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study 2024 ·Clinical Pharmacokinetics ·Mukul Minocha, Corbin G. Thompson, (unknown), Yanchen Zhou, Christian Brandl, (unknown), (unknown), (unknown), Pablo Martínez, Brett E. Houk	5
4	Efficiency and safety of Buzhong Tiaogan granule for treating the colorectal cancer patients with liver metastasis: study protocol for a multicenter randomized controlled trial 2024 ·Frontiers in Medicine ·(unknown), Yanchen Zhou, Xiaoli Li, Qiong Zhong, Likun Liu, Yu Gao, (unknown), (unknown), Lifang Yang	1
5	Synthesis of trifluoromethylated allenes via visible light-promoted bis(trifluoromethylation) of 1,3-enynes 2023 ·Journal of Fluorine Chemistry ·(unknown), Yanchen Zhou, Mingyou Hu	4
6	Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study 2022 ·ACR Open Rheumatology ·Lubna Abuqayyas, Laurence E. Cheng, (unknown), Barbara Sullivan, (unknown), Hui Wang, Yanchen Zhou, Vishala Chindalore, Stanley Cohen, Alan Kivitz, Maximilian Posch, Jane R. Parnes	12
7	Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions 2022 ·Cephalalgia ·Yanchen Zhou, Feng Zhang, (unknown), Zheng Hu, Cheng‐Pang Hsu, Po‐Wei Chen, (unknown), (unknown), Daniel T. Mytych, Gabriel Paiva da Silva Lima	8
8	A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females 2019 ·CNS Drugs ·Yang Xu, (unknown), Yi Wang, Yanchen Zhou, (unknown), (unknown), Daniel D. Mikol, Edward Lee	9
9	Use of near-infrared spectroscopy for the rapid evaluation of soybean [Glycine max (L.) Merri.] water soluble protein content 2019 ·Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy ·(unknown), Wei Hu, Yanchen Zhou, Xianyi Zhang, (unknown), (unknown), (unknown), Ling‐Ling Chen, (unknown), Fan Zhang, Like Liu, Lijuan Qiu, (unknown)	29
10	Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098) 2018 ·Neurology ·Bert B. Vargas, Amaal J. Starling, Stephen D. Silberstein, Yanchen Zhou, Marie‐Louise Trotman, Fei Xue, (unknown), Hernàn Picard, Daniel D. Mikol	5
11	A Proposal to Redefine Clinical Immunogenicity Assessment 2017 ·The AAPS Journal ·Daniel T. Mytych, M. Benjamin Hock, Mark A. Kroenke, Vibha Jawa, Arunan Kaliyaperumal, Yanchen Zhou	6
12	Protease inhibitors targeting coronavirus and filovirus entry breakdown → 2015 ·Antiviral Research ·Yanchen Zhou, P. Vedantham, Kai Lü, Juliet Agudelo, Ricardo Carrion, Jerritt Nunneley, Dale L. Barnard, Stefan Pöhlmann, James H. McKerrow, Adam R. Renslo, Graham Simmons	437
13	Development of novel entry inhibitors targeting emerging viruses 2012 ·Expert Review of Anti-infective Therapy ·Yanchen Zhou, Graham Simmons	44
14	Development and application of a high‐throughput microneutralization assay: lack of xenotropic murine leukemia virus–related virus and/or murine leukemia virus detection in blood donors 2012 ·Transfusion ·Yanchen Zhou, Imke Steffen, Leilani Montalvo, Tzong‐Hae Lee, (unknown), William M. Switzer, (unknown), Hongwei Jia, Walid Heneine, Valerie Winkelman, Chetankumar S. Tailor, Yasuhiro Ikeda, Graham Simmons	10
15	No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected 2011 ·Science ·Konstance Knox, Donald R. Carrigan, Graham Simmons, Fernando Teque, Yanchen Zhou, John Hackett, Xiaoxing Qiu, Ka‐Cheung Luk, Gerald Schochetman, (unknown), Andreas M. Kogelnik, Jay A. Levy	87
16	Inhibitors of SARS-CoV entry – Identification using an internally-controlled dual envelope pseudovirion assay 2011 ·Antiviral Research ·Yanchen Zhou, Juliet Agudelo, Kai Lü, David H. Goetz, Elizabeth Hansell, Yen‐Ting Chen, William Roush, James H. McKerrow, Charles S. Craik, Sean M. Amberg, Graham Simmons	19
17	No Evidence of Murine Leukemia Virus-Related Viruses in Live Attenuated Human Vaccines 2011 ·PLoS ONE ·William M. Switzer, Huiyuan Zheng, Graham Simmons, Yanchen Zhou, Shaohua Tang, Anupama Shankar, Beatrix Kapusinszky, Eric Delwart, Walid Heneine	8
18	Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin 2011 ·Antiviral Research ·Yohichi Kumaki, Miles K. Wandersee, Aaron Smith, Yanchen Zhou, Graham Simmons, (unknown), Kevin W. Bailey, (unknown), Joseph K.-K. Li, Paul K.S. Chan, Donald F. Smee, Dale L. Barnard	71
19	No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian Patients with Chronic Fatigue Syndrome 2011 ·PLoS ONE ·Imke Steffen, D. Lorne Tyrrell, (unknown), Leilani Montalvo, Tzong‐Hae Lee, Yanchen Zhou, Kai Lü, William M. Switzer, (unknown), Hongwei Jia, Darren Hockman, Deanna M. Santer, Michael Logan, (unknown), John Law, Michael Houghton, Graham Simmons	16
20	Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein 2009 ·Virology ·Beatriz Salvador, Yanchen Zhou, Alain Michault, Marcus O. Muench, Graham Simmons	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact